Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gensight BiologicsLTS:0RIM -6.01%22 3-1 Month Momentum % is -4.61% as of Aug. 19, 2026. GuruFocus rates LTS:0RIM with a GF Score™ of 22/100. The stock has 8 warning signs investors should review. Among 1,386 Biotechnology companies, Gensight Biologics ranks better than 55.27% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-19), Gensight Biologics's 3-1 Month Momentum % is -4.61%.
The industry rank for Gensight Biologics's 3-1 Month Momentum % or its related term are showing as below:
LTS:0RIM's 3-1 Month Momentum % is ranked better than 55.27% of 1386
companies
in the Biotechnology industry
Industry Median: -6.185
vs LTS:0RIM: -4.61
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gensight Biologics 3-1 Month Momentum % Related Terms
LTS:0RIM vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Gensight Biologics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gensight Biologics (LTS:0RIM) has a 3-1 Month Momentum % of -4.61% as of Aug. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #620 out of 1386 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Gensight Biologics' 3-1 Month Momentum % too high?
Gensight Biologics' current 3-1 Month Momentum % is -4.61%. Based on the distribution chart, Gensight Biologics ranks #620 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gensight Biologics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gensight Biologics' 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #620 out of 1386 companies for 3-1 Month Momentum %. This puts Gensight Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current 3-1 Month Momentum % is -4.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Gensight Biologics (LTS:0RIM) has a current 3-1 Month Momentum % of -4.61%. The current 3-1 Month Momentum % is -4.61%. Gensight Biologics' overall GF Score™ is 22/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Gensight Biologics (LTS:0RIM), the current 3-1 Month Momentum % is -4.61% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
22GF Score
Get the complete analysis for LTS:0RIM
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RIM has been successfully added to your 
